LASCCO SA is a pioneering biomedical-technology development company located at the Biopole of Lausanne, Switzerland. With a focus on advancing early-stage biomedical technologies, LASCCO is dedicated to bridging the gap between cutting-edge research institutes and the pharmaceutical industry. At the core of LASCCO's compelling portfolio are two critical care products.

These products harness innovative technologies to combat sepsis and effectively treat severe bacterial and viral infections. In recent news, LASCCO's partner and licensee, Eagle Pharmaceuticals, has announced the acceptance of an Investigational New Drug Application for CAL02. CAL02 represents a groundbreaking anti-virulence agent designed to tackle severe pneumonia.

Additionally, LASCCO is proud to present a webinar featuring their partner Abionic, discussing the clinical applications of Pancreatic Stone Protein. Under the guidance of their experienced team, led by Managing Directors Samareh Azeredo da Silveira and Frédéric Lajaunias, along with Chief Medical Director Toni Perez, LASCCO is at the forefront of driving biomedical discoveries. For inquiries or more information, please reach out to LASCCO using the provided contact details.

Copyright 2022 LASCCO SA | All Rights Reserved